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Objectives: The operative mortality and morbidity of patients with complicated acute type B aortic dissection
remain high. The endovascular approach has been proposed as a potential alternative. The purpose of this study
is to review the contemporary outcome of patients undergoing endovascular treatment for complicated acute type
B aortic dissection.
Methods: A retrospective analysis of 28 patients undergoing endovascular interventions for acute type B aortic
dissection was performed. Kaplan–Meier survival analysis was used for statistical computation.
Results: Indications for emergency endografting were rupture in 4 (14%) patients, severe lower body malperfu-
sion in 8 (29%) patients, visceral/renal malperfusion in 7 (25%) patients, persistent chest pain despite proper anti-
impulsive therapy in 5 (18%) patients, uncontrollable hypertension in 1 (4%) patient, and acute dilatation of false
lumen with impending rupture in 3 (11%) patients. Three (11%) patients died early. Three patients died during
follow-up of non–aorta-related causes. Overall survival was 82% and 78% at 1 and 5 years’ follow-up, respec-
tively. The aorta-related mortality was 10% for the entire follow-up period. Complete thrombosis of the false lu-
men in the thoracic aorta was achieved in 22 (85%) members of the surviving cohort, and partial thrombosis was
achieved in the remainder. The rate of treatment failure according to Stanford criteria was 18% at 5 years. Mean
follow-up was 36 months, and follow-up was complete in 28 (100%) patients.
Conclusions: Thoracic aortic endografting for complicated acute type B aortic dissection can be performed with
a relatively low postoperative morbidity and mortality in experienced hands. The endovascular approach to life-
threatening complications of acute type B aortic dissection appears to have a favorable outcome in midterm
follow-up.Acute type B dissection is a dramatic and catastrophic condi-
tion. The majority of patients with uncomplicated disease can
be treated conservatively with anti-impulsive and antihyper-
tensive therapy.1 However, up to 20% of these patients can
present with or later experience severe complications, such
as rupture, impending rupture, or branch–vessel malperfu-
sion.2 These challenging patients are usually triaged to surgi-
cal or endovascular management.
The surgical approach has been the standard of care for
the treatment of complicated type B aortic dissection. How-
ever, management has been challenging, even in centers of
excellence.3-5 The most recent results of surgical manage-
ment of acute type B aortic dissection were presented by
Bozinovski and Coselli.6 The in-hospital mortality was
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1 complication.6
For these reasons, thoracic endovascular aortic repair
(TEVAR) of acute aortic dissection has gained increasing
interest as an initial treatment option for patients with com-
plicated acute type B aortic dissection.7-9 The goal of this
therapy is to exclude the primary entry site, obliterate the
false lumen, prevent aortic rupture, and relieve lower body
malperfusion.
The aim of this study is to review the contemporary out-
come of patients undergoing endovascular treatment for
complicated acute type B aortic dissection.
MATERIALS AND METHODS
Seventy-two consecutive patients with type B aortic dissection under-
went TEVAR between August 1999 and July 2007 at the Harbor–UCLA
Medical Center and the University of Nebraska Medical Center. Twenty-
eight of these patients were admitted with complicated acute type B aortic
dissection. The rest had chronic type B aortic dissection and were excluded
from this study. Thirty procedures were performed in 19 (67.9%) male and
9 female patients. After obtaining approval from the institutional review
board, the patients were offered TEVAR through a single-institution inves-
tigator Investigational Device Exemption approved by the US Food and
Drug Administration. All patients signed consent forms for the use of these
investigational devices and agreed to participate in the surveillance proto-
cols after deployment of the devices.
Inclusion and Exclusion Criteria
All patients had complicated acute type B aortic dissections and were
candidates for TEVAR based on the adequacy of proximal and distalardiovascular Surgery c Volume 138, Number 3 625
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landing zones and access vessels. Furthermore, the patient’s arterial anat-
omy must have met device-specific requirements to be a candidate for TE-
VAR. Other inclusion criteria were signing the informed consent form and
agreeing to follow up in the institutional surveillance program.
The exclusion criteria included type A (or Retro-A) aortic dissection,
chronic type B aortic dissection, penetrating ulcer or intramural hematoma
of the descending thoracic aorta, an arterial anatomy unsuitable for TEVAR,
connective tissue disorders, age less than 18 years, pregnancy, hypercoag-
ulable disorder, and systemic infection. Advanced age or comorbidities
per se were not part of the exclusion criteria.
Definitions
Aortic dissection was classified as type B according to the Stanford clas-
sification if the dissection did not involve the ascending aorta or aortic arch.
The dissection was considered acute if the dissection presented within 2
weeks of the initial onset of symptoms. The term complicated dissection
was defined as malperfusion syndromes, rupture, impending rupture, and
persistent/unrelenting back pain or incontrollable hypertension despite max-
imal medical therapy.
Primary technical success was defined as complete exclusion of the pri-
mary tear site by the stent graft without procedural endoleak, death, or need
for conversion to open repair. Treatment failure was defined according to the
Stanford criteria as aortic rupture, device mechanical fault, reintervention,
aorta-related death, or sudden or unexplained late death.10 Endoleaks
were reported as defined by the reporting standard of Chaikof and col-
leagues.11
Imaging/Endovascular Techniques
Endovascular techniques used for TEVAR have been described in previ-
ous publications.12-15 All procedures were performed in the endovascular
suite or operating room with C-arm fluoroscopy. Intravascular ultrasono-
graphic analysis was used as adjunct imaging in every case to ensure loca-
tion of the guidewire in the true lumen, assist with sizing of the stent graft,
and evaluate the location of the primary intimal tear and the intraoperative
end points of TEVAR (complete exclusion of the primary intimal tear and
stagnation of blood flow in the false lumen). Continuous intraoperative
transcranial Doppler monitoring was performed in the last 11 patients.
The follow-up physical examination, contract computed tomographic
(CT) scanning, and laboratory work were performed according to the insti-
tutional surveillance protocol at 1, 6, and 12 months and yearly thereafter.
The protocol for postoperative imaging includes a 3-phase multidetector
CT angiogram. A noncontrast scan through the chest and abdomen is fol-
lowed by contrast CT angiographic analysis with 100 mL of nonionic con-
tract. A 2-minute delayed CT scan is performed to increase the detection rate
for endoleaks.
Statistical Analysis
Patient data, including demographics, risk factors, clinical symptoms,
procedural details, CT scans, angiograms, postoperative complications, sec-
ondary interventions, and mortality, were collected in a retrospective man-
ner by means of chart review and by means of review of prospective and
concurrent US Food and Drug Administration reports of the respective In-
vestigational Device Exemption protocols. All data were entered into an
electronic database. Statistical analysis was performed with the SPSS
13.0 for Windows statistical software package (SPSS, Inc, Chicago, Ill).
The actuarial survival rate was computed according to the Kaplan–Meier626 The Journal of Thoracic and Cardiovascular Sulog-rank method. The statistical analysis underwent a mathematic review
by a biostatistician.
RESULTS
Preoperative characteristics and outcomes of the patients
undergoing TEVAR for complicated type B aortic dissection
are summarized in Table 1. Indications for emergency TEVAR
were rupture in 4 (14%) patients, severe lower body malperfu-
sion in 8 (29%) patients, visceral/renal malperfusion in 7
(25%) patients, persistent chest pain despite proper anti-
impulsive therapy in 5 (18%) patients, uncontrollable hyper-
tension in 1 (4%) patient, and acute dilatation of false lumen
with impending rupture in 3 (11%) patients. The latter was
characterized by an enlarged aortic diameter in the dissected
region with evidence of hemothorax and no active contrast
extravasations in the CT imaging. Twenty-five patients under-
went endovascular repair with the Talent device (Medtronic,
Minneapolis, Minn). The TAG device (Gore, Flagstaff,
Ariz) was deployed in the remaining 5 patients.
Adjunct procedures were necessary in 3 patients with
static or combined dynamic and static obstruction of the
branched vessels. Fenestration of the distal aortic dissection
membrane was performed in a 63-year-old man with subse-
quent relief of visceral and limb ischemia. The postopera-
tive course was complicated by multiorgan dysfunction,
adult respiratory distress syndrome, and deterioration of re-
nal function (without requiring hemodialysis). However, he
fully recovered and has done well in more than 7 years of
follow-up. A 58-year-old man with altered mental status
and paraplegia on presentation was treated with fenestration
of the perirenal aorta obviating the hemodialysis. Although
his renal function normalized within the next 7 days, he re-
mains paraparetic in the follow-up period. A 72-year-old
patient with gut ischemia and severe lactic acidosis under-
went salvage fenestration of an infradiaphragmatic aorta
and antegrade stenting of the superior mesenteric artery.
Retrograde access to the superior mesenteric artery was
not achieved because of static obstruction of the visceral
vessels. He died of multiorgan dysfunction syndrome on
postoperative day 2.
Early and Late Mortality
There were no intraprocedural deaths. The in-hospital,
early, and aorta-related mortality was 10.7% (3/28), respec-
tively. Two patients died of visceral ischemia and multior-
gan dysfunction syndrome on postoperative days 2 and 3.
A third patient died of retrograde type A dissection on post-
operative day 8. Three additional patients died in the follow-
up period (pneumonia in 2 patients and malignancy in the
third patient). Overall survival according to Kaplan–Meier
analysis was 82% and 78% at 1 and 5 years’ follow-up, re-
spectively (Figure 1). The mean follow-up was 36 months
(standard deviation,  27 months; range, 1–88 months),
and follow-up was complete in all patients.rgery c September 2009
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Primary technical success was achieved in 27 (90%) of
30 patients. In 3 patients there was a small type Ia endoleak
at the end of the procedure. Although the endoleak sub-
sided in 1 patient after reversal of heparin and on subse-
quent follow-up imaging, the second patient required
a reintervention to improve the apposition of the stent graft
to the proximal landing zone. A third patient died of sudden
death on postoperative day 8 (as described above). The
autopsy examination revealed retrograde type A aortic
dissection, which was not present on the day of the opera-
tion. No patient underwent conversion to open repair. There
were no aortic ruptures in the follow-up period. The rate of
treatment failure according to Stanford criteria was 5
(18%) of 28 at 5 years.
During the follow-up period, there were 3 (aforemen-
tioned) early endoleaks (10%), and a total of 5 (20%) of
25 late endoleaks (endoleaks after 30 days): 80% (4/5)
were type Ib endoleaks, and 5% (1/5) were type III
endoleaks. Two patients required secondary interventions.
A 40-year-old woman had proximal maldeployment and
kinking of the stent graft. As mentioned above, she under-
went re-expansion of the proximal neck with a Palmaz
stent on postoperative day 2. A 63-year-old man continued
to have visceral malperfusion requiring additional stent
grafting of secondary intimal tears in the descending tho-
racic aorta and fenestration. No further secondary interven-
tions were performed to treat an endoleak in the follow-up
period.
TABLE 1. Perioperative demographics of the patients
Characteristics All patients (n ¼ 28)
Age, y (median) 62  15 (range, 35–88)
Preoperative neurologic deficit (3 strokes
and 1 paraplegia)
4 (14%)
s/p aortic surgery (4 open abdominal aortic
aneurysm repairs and 1 ascending aortic
replacement)
5 (18%)
Preoperative creatinine (mg/dL) 1.5  1.4
Coronary artery disease 49 (26%)
Preoperative myocardial infarction 1 (3%)
Congestive heart failure 4 (14%)
Chronic obstructive pulmonary disease 7 (25%)
Peripheral vascular disease 3 (11%)
Postoperative stroke 1 (3.3%)
Postoperative paraplegia 0
Need for iliac conduit 3 (10%)
ICU stay, d (median) 4  5.3
Hospital stay, d (median) 8  8.5
Acute renal failure (creatinine 1.8 mg/dL) 3 (10%)
Contrast injected (mL) 122  70
Fluoroscopic time (min) 10.9  7.7
Median operative time (min) 152  165
s/p, Status post; ICU, intensive care unit.The Journal of Thoracic andPatency of False Lumen
Complete obliteration of the false lumen was achieved in
22 (88%) patients in the follow-up period, and partial throm-
bosis was present in the remainder (Figure 2). In 3 patients
with partial thrombosis, the false lumen was patent in the
distal one third of the thoracic aorta and abdominal aorta
in 2 patients, whereas 1 patient had evidence of false lumen
perfusion in solely the abdominal aorta. On the latest imag-
ing, the maximal aortic diameter and aortic volume in-
creased in both patients with a persistent false lumen in
the thoracoabdominal aorta.
DISCUSSION
Endovascular management of complicated acute type B
dissection is complex and challenging. It has become an
emerging alternative to open repair in many centers since
its initial feasibility and safety was demonstrated by the
Stanford group.16 The indications for endovascular therapy
for complicated acute type B aortic dissection have yet to
be determined. In the current era, the purest indications for
TEVAR in the setting of acute type B aortic dissection are
malperfusion and rupture. These critically ill patients have
very high open surgical mortality, even in centers of excel-
lence.3,6 Although validation studies comparing surgical
therapy with TEVAR are missing, the endovascular ap-
proach has been used increasingly for these indications.17
The majority of patients in the current study (85%) were
treated for malperfusion rupture or impending rupture. Six
other patients were treated for unrelenting chest/back pain
or uncontrollable hypertension. These later indications are
‘‘softer calls’’ for TEVAR for acute type B aortic dissection.
However, intractable pain is thought to be a symptom of pro-
gression of dissection, possible impending rupture, or mal-
perfusion, necessitating endovascular intervention.6,10,17,18
FIGURE 1. Kaplan–Meier survival curve. Tick marks indicate at least 1
patient censored because of length of follow-up.Cardiovascular Surgery c Volume 138, Number 3 627
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puted tomographic scan demonstrates complete thrombosis of the false lumen of the proximal and mid descending thoracic aorta at 1 year’s follow-up. The
false lumen of the distal descending thoracic aorta takes another 2 years to completely clot because of multiple re-entry sites in the abdominal aorta. The false
lumen in the abdominal aorta remains perfused at 3 years’ follow-up.Uncontrollable hypertension is a less common problem with
modern antihypertensive and anti-impulsive strategies.19,20
However, dissection into the renal arteries can cause poorly
controlled or uncontrollable arterial hypertension because of
an uncoupled renin–angiotensin–aldasterone system. Al-
though these patients might not have increased creatinine
levels and frank renal ischemia, many authors postulate sur-
gical intervention or TEVAR to reduce the chance of rupture
or early aneurysmal degeneration in the proximal descend-
ing thoracic aorta.6,10,19 As increased follow-up and experi-
ence has been gained for TEVAR in various patients with
complicated acute type B aortic dissection, we hope to refine
patient selection criteria and enhance physician judgment
along with the evolution of more sophisticated, small-cali-
ber, flexible, and pathology-specific TEVAR devices and
deployment systems.
The aim of this study was to report the contemporary out-
come of patients undergoing TEVAR for complicated acute
type B aortic dissection. To the best of our knowledge, this
series is the largest with complete 3-year average follow-up
published in the literature. All patients underwent close and
complete follow-up because of stringent study protocols and
strict regulatory reasons. The results of this study are in con-
cordance with those of the series reported originally by the
Stanford group.10 Sixteen patients were treated with
TEVAR for complicated type B aortic dissection (rupture,
hemothorax, refractory chest pain, and/or severe visceral
or lower limb ischemia) in this series. Early mortality was
23%, with no late deaths. Based on the latest scan, 4628 The Journal of Thoracic and Cardiovascular Sur(25%) patients had complete thrombosis of the false lumen,
and 6 (38%) patients had partial thrombosis. Aortic diame-
ter increased in 1 patient. Actuarial survival was 73% at 1-
and 5-year intervals. The actuarial estimate of freedom from
treatment failure was 67% at 5 years.10 A similar range of
early survival, primary technical success, and treatment fail-
ure has been reported in the literature.17,21-24
Complete obliteration of the false lumen is one of the
important goals in the follow-up of patients with acute
type B aortic dissection. The European multicenter study
by Erbel and coworkers25 showed that late outcome was
better in patients with a thrombosed false lumen than in
those with a patent false lumen. In the current study 22
of 25 early survivors had complete obliteration of the false
lumen in the thoracoabdominal aorta. This high rate of aor-
tic ‘‘reverse remodeling’’ is possible when the patient is
treated early after development of the dissection flap.
With progression of time, the dissection flap becomes
more fibrosed, thickened, and matured, making it less
compliant to TEVAR.
There are several limitations to the current study. It repre-
sents a retrospective analysis of prospectively collected data
as part of investigational protocols at 2 institutions. There is
a lack of a risk-adjusted control group undergoing open re-
pair for similar aortic pathologies. A larger trial with a mul-
ticenter registry is recommended to substantiate the findings
in this study and to establish long-term (10 years) durabil-
ity and safety of the stent grafts in complicated acute type B
aortic dissection.gery c September 2009
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stent grafts intended for treating aneurysms and have gone
through a learning curve for this new technology. Some of
the morbidities and mortalities encountered in the current se-
ries might be reduced/obviated based on our current experi-
ence. For instance, to reduce the possibility of retrograde
type A aortic dissection, we do not balloon dilate the proxi-
mal landing zone and avoid oversizing by more than 15%.
Device sizing is performed based on the normal proximal
aorta after the left common carotid artery. The primary end
points of endovascular interventions are coverage of the
primary entry site, relief of malperfusion (if present), and
stagnation of blood in the false lumen. Intravascular
ultrasonographic scanning has been instrumental in negotia-
tion of the true lumen, accurate measurement of the dimen-
sions of the proximal landing zone, visualization of (large)
secondary entry sites, and evaluation for stagnation of blood
in the false lumen after the obliteration of the primary entry
site. In case of frank ruptures, impending ruptures, uncon-
trolled hypertension, and unrelenting pain, the entire aorta
between the subclavian and celiac arteries is covered. The
availability of a dissection-specific stent graft should im-
prove our outcomes in cases of malperfusion; we would
cover the primary (or large) secondary entry site and use
a bare stent to expand the true lumen throughout the length
of the descending thoracic aorta.
In brief, this series is (to the best of our knowledge) the
largest cohort with the longest follow-up in the literature,
demonstrating favorable early and midterm results for pa-
tients undergoing TEVAR for complicated acute type B aor-
tic dissection. Although long-term durability of TEVAR for
complicated acute type B aortic dissection is yet to be estab-
lished, we conclude that TEVAR is the therapy of choice for
patients with complicated acute type B aortic dissection and
that a paradigm shift is warranted from open surgical treat-
ment to TEVAR in these undesirable surgical candidates.
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Discussion
Dr D. Craig Miller (Stanford, Calif). Ali, this is very good. We
have to be careful with you here because ‘‘alihi’’ in Hawaiian
means ‘‘chief,’’ and that is close to Ali.
I have no objections whatsoever to your talk this morning, which
is a far cry from what I said last year in New Mexico.
Dr Khoynezhad. I remember that very well. (laughter)
DrMiller. I bet you do, and if you keep coming back every year,
some day we will make you an honorary member, just like Urschel
and Walt Wolfe, so welcome back to the Western Thoracic Asso-
ciation.
I really do appreciate you bringing this material to our attention
because I agree with you wholeheartedly that the best and most life-ardiovascular Surgery c Volume 138, Number 3 629
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actly these patients: patients with acute type B aortic dissection
with complications, who are dying right under your eyes. It is prob-
ably the application that is being less applied certainly worldwide
and maybe even in the United States. Therefore you have tackled
the toughest patients, and I think you have shown some spectacular
results of which you should be proud.
I really do agree with all your conclusions this year. I have a co-
uple quibbles, and it would not be correct if I did not, right? You
had very tight inclusion/exclusion criteria. I am wondering what
happened and how many there were who were excluded from stent
grafting because they were too sick, could not sign, or did not have
the right anatomy. Do you have any idea what your internal control
group was and how well they did?
Dr Khoynezhad. In regard to open operations?
Dr Miller. Whatever you did.
Dr Khoynezhad. We had 3 patients who required open opera-
tions in the follow-up period. The first patient was operated on at
Creighton University, and 2 patients were operated on at Harbor–
UCLA. In the latter 2 patients, we did not have adequate access
to vessels. The size of the iliac arteries was not adequate for endo-
vascular procedures. Both patients underwent open operations. The
third patient had an emergency operation for a ruptured acute type
B aortic dissection at Creighton University. I try to avoid doing
those operations as much as I can. Having said that, exclusion cri-
teria were severe acidosis, refusal of treatment, no vital signs, any
type A dissections, retro-A dissections, chronic dissection (ie, 14
days after symptoms), and any intramural hematoma or aortic ul-
cers. Any connective tissue disorders were not treated with endo-
vascular treatment either.
Dr Miller. That is fine. I was just getting to the ones who were
too sick and dying. You were going to end up doing a warm autopsy
one way or another.
Dr Khoynezhad. There are patients with type A or type B dis-
sections who are not offered open or endovascular procedures.
There are some patients who are too sick. They are severely aci-
dotic, and they decide not to be treated at all, or the patient’s family
declines to do that. I do not have the number for those.
Dr Miller. I am not sure these can truly be called midterm re-
sults. You did not show us in your graft or in the manuscript how
many were remaining at risk at 2, 3, 4, and 5 years and particularly
how many of those had a current CT scan. I will bet you the num-
bers are small, less than a handful, out beyond 2 years, and therefore
it might be more appropriate to term this article ‘‘early results.’’
Dr Khoynezhad. Your point is well taken.
DrMiller.Can you give us some numbers remaining at risk at 2,
3, or 4 years?
Dr Khoynezhad. We started performing endovascular treat-
ment of complicated type B aortic dissection at Harbor–UCLA in
1999 after the initial publication from the Stanford group. I think
we have 20 patients remaining at risk at 1 year, 17 at 2 years, 13
at 3 years, 10 at 4 years, 6 at 5 years, and 2 at 6 years.
DrMiller. That is the safe way. We did that the same in our 2005
paper presented in Victoria, which Dr Cohn hopefully will be pub-
lishing soon in the Journal. (laughter) We had 8 patients at 3 years
and 6 patients at 5 years, and you just cannot say anything with such
a small number of patients out at the end of the curves.
Dr Khoynezhad. Absolutely.630 The Journal of Thoracic and Cardiovascular SurDr Miller. A word of caution. In the ruptures you want to cover
the entire descending thoracic aorta, and I understand why because
you have no idea where they are ruptured, but you only have 4 rup-
tures. If you do that in enough patients, you are going to pay a price,
and the price can be paraplegia. I think we should be cautious. It
reminds me of Frank Criado, a vascular surgeon where Ali got
his training at Torrance, saying to cover it all with impunity. That
does not work out in the patient’s best interest all the time. I would
have to disagree with you there, even though you are flying blind.
You do not know where the actual leak is.
I also have an affirmation. You make 2 pleas in your manuscript.
You say that we have to categorize these patients strictly. I could
not agree more because there is a lot of fuzziness in how these pa-
tients are presented. Second, we have to have uniform standardized
outcome-reporting guidelines. It was very heartwarming to me that
you are using the Stanford treatment failure definition, which is an
overestimate, very comprehensive and too high, but at least it will
be a level playing field. We can apply it from center to center and
make these comparisons in a more meaningful fashion.
Your 82% freedom from treatment failure at 5 years is spectac-
ularly good. Our number was 67% at 5 years.
There are members in the audience who might say your 30% en-
doleaks is bad, and this represents a failure of therapy. That is not at
all correct. These are acute dissections. Our goal is not to get all the
blood flow out of the false lumen. Our goal is to save lives, and that
means to pop open the true lumen, improve the malperfusion, re-
suscitate the patient, and then maybe deal with the persistently pat-
ent false lumen another way when they are in much better
condition. Therefore I do not interpret that as failure in this context,
and I applaud you for pointing that out to the readers.
DrKhoynezhad. I think endovascular treatment for complicated
type B aortic dissection might not be curative for many patients, but
it saves lives in the acute phase, and we always have options to treat
patients with open or endovascular means in the future.
DrMiller. The definition should be applied across the board, ab-
solutely. It is the only way to be fair.
Finally, I applaud what you are doing in Omaha at the University
of Nebraska. You are a cardiothoracic surgeon. You did your endo-
vascular training with peripheral vascular surgeons. That represents
a failure of our CT training structure in this country right now.
Hopefully it will improve in the future, but you are outgrowing
those bad habits you might have learned in Torrance, and you are
doing what is best for the patient in Omaha. Congratulations.
Dr Royce Calhoun (Sacramento, Calif). Ali, I enjoyed your
talk as well. As you know, we stent a lot of traumatic patients,
which I think actually is another subset that benefits from this
technology, although Dr Miller, I am sure, will take some issue
with that. Nonetheless, we see a lot of these patients too, and
we have not been as aggressive stenting them. I think the whole
pain and uncontrolled hypertension thing is such a vague sur-
geon-dependent judgment. In at least the ones that we deal
with, and we deal with probably 20 to 30 of these a year, that re-
ally represents—First of all, they are mostly not complicated.
They are mostly uncomplicated once we get their blood pressure
down. Of the ones that are complicated, usually it is sort of vague
pain, waxing and waning, and hypertension. Of your group, and I
realize most of this probably represents Harbor’s data, do you
know how many of those were truly a sort of malperfusion orgery c September 2009
Khoynezhad et al Acquired Cardiovascular Diseasesomething where you really had to act versus a judgment about
blood pressure management or something like that?
Dr Khoynezhad. Fifteen patients had malperfusion; 8 had
malperfusion of the lower extremities, and 7 had visceral/renal
malperfusion. As you mentioned, uncontrolled hypertension or
pain is a soft call for this procedure. This was the case in 6
patients. That is one of the points in this article, if Dr Cohn agrees
to publish it. (laughter) The point is basically that we have to
define maximal medical therapy. At my institution, I have estab-
lished a protocol: 3 parenteral antihypertensive medications haveThe Journal of Thoracic and Cto be initiated before we call that case a failure of medical treat-
ment. This has not been addressed in a majority of articles that
I see in the literature currently on complicated acute type B dis-
sections. Having said that, operating on patients with unrelenting
pain or incontrollable hypertension has been the standard of care
for open surgical repair. Therefore it is fair to treat those patients
also endovascularly. These patients who continue to have pain are
operated on in aortic centers of excellence, such as the one in
Houston with Dr Safi, with whom I have had the privilege and
pleasure to work early in my career.ardiovascular Surgery c Volume 138, Number 3 631
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